Uncertainty around future drug developments could hold back the stock price of Bristol-Myers Squibb, according to Morgan Stanley.
Analyst David Risinger downgraded the stock to equal weight from overweight on Friday, saying that the long-term picture for the company’s earnings power was getting less positive.
